The frequency of global crises such as hurricanes, war, and the pandemic makes a standing committee necessary.
The Community Oncology Alliance (COA) has launched a new standing Humanitarian Aid Committee, which will coordinate aid for those affected by war, natural disasters, and other crises. The group’s first effort will be supporting 4 medical charities that are assisting those affected by the war in Ukraine: Americares, Direct Relief, Doctors Without Borders, and International Medical Corps. A webpage for the committee can be found here.
A statement from COA released Monday says that although the group’s mission is based in the United States, “the greater oncology community has a responsibility to act and engage on a global scale during times of crisis.” COA has worked with other groups on hurricane relief efforts and on the global effort to keep patients safe during the COVID-19 pandemic.
The frequency of such events makes a standing committee necessary, the group said.
“Cancer isn’t localized to one country or region of the world, and it certainly doesn’t become less important during times of crisis,” said Mark Thompson, MD, COA’s medical director of public policy. “As people are displaced and seek shelter, it’s our responsibility to help them continue treatment. Cancer doesn’t stop during an emergency. COA’s mission to fight cancer doesn’t either.”
The Humanitarian Aid Committee will include both volunteers and staff. Current members include:
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More